Related Experiment Video
Updated: Jun 10, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Doramectin Induces Apoptosis in B16 Melanoma Cells
Megan S Crotts1,2, Jena C Jacobs1,2, Robert W Baer1,2
1Department of Biochemistry, Kirksville College of Osteopathic Medicine, A.T. Still University of Health Sciences, Kirksville, Missouri, USA.
Introduction/Objective:
Metastatic melanoma resists current pharmacological regimens that act through apoptosis. This indicates that therapies acting via non-apoptotic cell-death pathways could be pursued. Doramectin has shown promising results in another cancer of neural crest origin, neuroblastoma, through the inhibition of growth via autophagy. Our research hypothesis is that doramectin induces autophagy in B16F10 melanoma cells.
Methods:
Cells were treated with doramectin (15 uM) or a combination of both doramectin and a cell-death inhibitor, compared to untreated control cells (media), and then analyzed with MTT analysis. Likewise, MDC analysis was completed to detect autophagy involvement with doramectin treatment. Flow cytometry and TUNEL Assay were conducted to observe cell death-related effects.
Results:
MTT analysis of doramectin-treated cells displayed a decrease in cell growth compared to control. Apoptotic morphology was prominent in melanoma cells treated with doramectin. Increased autophagy was not detected by fluorometric microscopic analysis. Flow cytometry analysis of doramectin-treated cells showed apoptosis as a major mode of cell death with some necrosis.
Conclusion:
Doramectin induces a novel cell-death mechanism in melanoma compared to other forms of cancer and should be studied as an effective anti-cancer agent for melanoma treatment.
Insights
Doramectin treatment reduced melanoma cell growth and induced apoptosis, a cell death pathway distinct from autophagy. Further research is warranted for its potential as an anti-melanoma agent.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Metastatic melanoma often resists conventional apoptosis-inducing therapies.
- Alternative cell-death pathways are being explored for melanoma treatment.
- Doramectin has shown efficacy in neuroblastoma by inhibiting growth via autophagy.
Purpose of the Study:
- To investigate if doramectin induces autophagy in B16F10 melanoma cells.
- To explore doramectin's mechanism of action in melanoma.
- To evaluate doramectin as a potential anti-cancer agent for melanoma.
Main Methods:
- B16F10 melanoma cells were treated with doramectin.
- MTT analysis assessed cell viability and growth inhibition.
- MDC analysis, flow cytometry, and TUNEL assays were used to detect autophagy and cell death.
- Cells were also treated with a combination of doramectin and a cell-death inhibitor.
Main Results:
- Doramectin treatment significantly decreased melanoma cell growth.
- Apoptotic morphology was observed in doramectin-treated cells.
- Flow cytometry indicated apoptosis and some necrosis as primary cell death mechanisms, not autophagy.
- MDC analysis did not detect increased autophagy.
Conclusions:
- Doramectin induces apoptosis and necrosis in melanoma cells, not autophagy.
- This represents a novel cell-death mechanism for melanoma treatment.
- Doramectin warrants further investigation as a potential anti-melanoma therapeutic agent.
